Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 6
Submit an article Journal homepage
343
Views
7
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study

Lingyun WuDepartment of Hematology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
,
Xiao LiDepartment of Hematology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, ChinaCorrespondence[email protected]
,
Chunkang ChangDepartment of Hematology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
,
Feng XuDepartment of Hematology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
,
Qi HeDepartment of Hematology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
,
Dong WuDepartment of Hematology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
,
Zheng ZhangDepartment of Hematology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
,
Jiying SuDepartment of Hematology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
,
Liyu ZhouDepartment of Hematology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
,
Luxi SongDepartment of Hematology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
,
Xiao ChaoDepartment of Hematology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
&
Youshan ZhaoDepartment of Hematology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
 show all
Pages 1367-1374 | Received 19 May 2015, Accepted 15 Sep 2015, Published online: 16 Nov 2015

References

  • Adès L, Itzykson R, Fenaux P. Myelodysplastic syndromes. Lancet 2014; 383: 2239–2252.
  • Xiao L, Qi Z, Qiusheng C, et al. The use of selective immunosuppressive therapy on myelodysplastic syndromes in targeted populations results in good response rates and avoids treatment-related disease progression. Am J Hematol 2012; 87: 26–31.
  • Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009; 361: 1872–1885.
  • Itzykson R, Fenaux P. Epigenetics of myelodysplastic syndromes. Leukemia 2014; 28: 497–506.
  • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223–232.
  • Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794–1803.
  • Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009; 27: 3842–3848.
  • Wu Lingyun, Li Xiao, Su Jiying, et al. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome. Leuk Lymphoma 2009; 50: 1461–1467.
  • Wu L, Li X, Su J, et al. Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS. J Cancer Res Clin Oncol 2011; 137: 1563–1569.
  • Liu H, He GS, Wu DP, et al. Clinical efficacies and safety of HAG regimen for patients with high-risk myelodysplastic syndromes: a multicentre study. Zhonghua Yi Xue Za Zhi 2012; 92: 689–691.
  • Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292–2302.
  • Bennett JM, Catovsky D, Daniel MT. Proposals for the classification of the acute leukaemias: French-American-British Cooperative Group. Br J Haematol 1976; 33: 451–458.
  • Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088.
  • Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006; 108: 1497–1503.
  • Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176–181.
  • de Witte T, Suciu S, Verhoef G, et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 2001; 98: 2326–2331.
  • Li X, Chang C, He Q, et al. Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine. Leuk Res 2013; 37: 1516–1521.
  • Wang J, Yi Z, Wang S, Li Z. The effect of decitabine on megakaryocyte maturation and platelet release. Thromb Haemost 2011; 106: 337–343.
  • Schmelz K1, Wagner M, Dörken B, Tamm I. 5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. Int J Cancer 2005; 114: 683–695.
  • Lee JH, Jang JH, Park J, et al. A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome. Haematologica 2011; 96: 1441–1447.
  • Oki Y, Kondo Y, Yamamoto K, et al. Phase I/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in Japan. Cancer Sci 2012; 103: 1839–1847.
  • Sekeres MA. Managing patients with higher-risk myelodysplastic syndrome with stable disease on hypomethylating agents. Leuk Lymphoma 2015; 11. [Epub ahead of print]. DOI: 10.3109/10428194.2015.1063149.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.